Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Ratios and Metrics

Market cap in millions USD. Fiscal year is September - August.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	38	8	18	32	31	54
Market Cap Growth	99.66%	-51.77%	-44.52%	1.25%	-42.21%	-63.81%
Enterprise Value	33	7	12	20	30	53
PE Ratio	-	-1.27	-2.42	-7.88	-7.97	-13.24
PS Ratio	97.22	37.56	68.97	43.93	99.61	243.74
PB Ratio	5.75	2.79	2.22	2.39	12.42	22.77
P/FCF Ratio	-6.91	-1.44	-3.57	-7.96	-11.97	-14.86
P/OCF Ratio	-6.91	-1.44	-3.61	-7.96	-11.97	-18.05
EV/Sales Ratio	85.19	31.75	45.05	27.80	95.93	237.68
EV/EBITDA Ratio	-5.99	-1.10	-1.59	-4.99	-7.69	-12.91
EV/EBIT Ratio	-5.76	-1.07	-1.56	-4.80	-7.39	-12.72
EV/FCF Ratio	-6.02	-1.21	-2.33	-5.04	-11.53	-14.49
Debt / Equity Ratio	0.02	0.05	0.01	0.01	0.06	-
Debt / EBITDA Ratio	-0.03	-0.03	-0.01	-0.02	-0.04	-
Debt / FCF Ratio	-0.03	-0.03	-0.01	-0.02	-0.06	-
Quick Ratio	63.51	6.17	32.79	78.90	7.20	8.79
Current Ratio	66.29	8.04	35.96	81.18	8.53	9.86
Asset Turnover	0.08	0.05	0.03	0.08	0.12	0.06
Interest Coverage	-5441288.00	-	-	-	-	-
Return on Equity (ROE)	-123.00%	-142.80%	-72.20%	-43.20%	-155.50%	-139.50%
Return on Assets (ROA)	-119.00%	-137.50%	-72.50%	-42.20%	-144.60%	-117.50%
Return on Capital (ROIC)	-78.88%	-203.67%	-82.75%	-31.16%	-154.73%	-173.81%
Earnings Yield	-14.51%	-78.45%	-41.27%	-12.68%	-12.55%	-7.56%
FCF Yield	-13.88%	-69.63%	-27.98%	-12.57%	-8.35%	-6.73%
Buyback Yield / Dilution	-80.90%	-12.38%	-34.02%	-58.34%	-6.95%	-9.63%
Total Shareholder Return	-80.90%	-12.38%	-34.02%	-58.34%	-6.95%	-9.63%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).